Kevin J Cameron - Net Worth and Insider Trading

Kevin J Cameron Net Worth

The estimated net worth of Kevin J Cameron is at least $593,598 dollars as of 2024-04-28. Kevin J Cameron is the Director of Keryx Biopharmaceuticals Inc and owns about 176,666 shares of Keryx Biopharmaceuticals Inc (KERX) stock worth over $593,598. Details can be seen in Kevin J Cameron's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Kevin J Cameron has not made any transactions after 2018-06-18 and currently still holds the listed stock(s).

Transaction Summary of Kevin J Cameron

To

Kevin J Cameron Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kevin J Cameron owns 1 companies in total, including Cutera Inc (CUTR) .

Click here to see the complete history of Kevin J Cameron’s form 4 insider trades.

Insider Ownership Summary of Kevin J Cameron

Ticker Comapny Transaction Date Type of Owner
CUTR Cutera Inc 2023-05-19 director

Kevin J Cameron Latest Holdings Summary

Kevin J Cameron currently owns a total of 1 stock. Kevin J Cameron owns 176,666 shares of Keryx Biopharmaceuticals Inc (KERX) as of June 18, 2018, with a value of $593,598.

Latest Holdings of Kevin J Cameron

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
KERX Keryx Biopharmaceuticals Inc 2018-06-18 176,666 3.36 593,598

Holding Weightings of Kevin J Cameron


Kevin J Cameron Form 4 Trading Tracker

According to the SEC Form 4 filings, Kevin J Cameron has made a total of 0 transactions in Keryx Biopharmaceuticals Inc (KERX) over the past 5 years. The most-recent trade in Keryx Biopharmaceuticals Inc is the sale of 1,667 shares on June 18, 2018, which brought Kevin J Cameron around $8,302.

Insider Trading History of Kevin J Cameron

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Kevin J Cameron Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Kevin J Cameron Ownership Network

Ownership Network List of Kevin J Cameron

No Data

Ownership Network Relation of Kevin J Cameron


Kevin J Cameron Owned Company Details

What does Cutera Inc do?

Who are the key executives at Cutera Inc?

Kevin J Cameron is the director of Cutera Inc. Other key executives at Cutera Inc include Interim Chief Financial Office Stuart Drummond , Chief Operating Officer Jeffrey S Jones , and director & Chief Executive Officer David H Mowry .

Cutera Inc (CUTR) Insider Trades Summary

Over the past 18 months, Kevin J Cameron made no insider transaction in Cutera Inc (CUTR). Other recent insider transactions involving Cutera Inc (CUTR) include a net purchase of 30,000 shares made by Taylor C. Harris , and a net purchase of 5,000 shares made by Stuart Drummond .

In summary, during the past 3 months, insiders sold 0 shares of Cutera Inc (CUTR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cutera Inc (CUTR) were sold and 35,000 shares were bought by its insiders, resulting in a net purchase of 35,000 shares.

Cutera Inc (CUTR)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Cutera Inc Insider Transactions

No Available Data

Kevin J Cameron Mailing Address

Above is the net worth, insider trading, and ownership report for Kevin J Cameron. You might contact Kevin J Cameron via mailing address: C/o Keryx Biopharmaceuticals, Inc., 750 Lexington Avenue, New York Ny 10022.

Discussions on Kevin J Cameron

No discussions yet.